Every issue of Clinical and Applied Thrombosis/Hemostasis (CATH) addresses the practical clinical and laboratory issues involved in managing bleeding and clotting disorders, especially those related to thrombosis, hemostasis, and vascular disorders. CATH offers comprehensive coverage of the topics that matter most to your work, including clinical trials, studies on etiology, pathophysiology, diagnosis and treatment of thrombohemorrhagic disorders, assessment of new clinical diagnostic procedures, pharmacological agents, laboratory diagnostic procedures, and patient management plans. CATH continually evaluates new research in areas including essential drugs such as Warfarin, Heparin, low-molecular-weight Heparin, and other emerging drug therapies; the clinical impact on treatment of diseases and conditions such as diabetes, hypertension, pregnancy, hemophilia, and HIV-AIDS; factor defects; platelet disorders; fibrinolytic disorders; DNA/RNA research; and ethnic and population differences in thrombohemorrhagic disorders.

《臨床及應(yīng)用血栓/止血》(CATH)的每一期都針對(duì)管理出血和凝血障礙，特別是與血栓形成、止血和血管疾病相關(guān)的臨床和實(shí)驗(yàn)室實(shí)際問(wèn)題。CATH提供對(duì)您的工作最重要的主題的全面覆蓋，包括臨床試驗(yàn)、病因?qū)W研究、病理生理學(xué)、血栓出血疾病的診斷和治療、新臨床診斷程序的評(píng)估、藥理制劑、實(shí)驗(yàn)室診斷程序和患者管理計(jì)劃。CATH不斷評(píng)估在華法林、肝素、低分子肝素等基礎(chǔ)藥物和其他新興藥物治療領(lǐng)域的新研究;對(duì)糖尿病、高血壓、妊娠、血友病、HIV-AIDS等疾病和條件治療的臨床影響;因素的缺陷;血小板疾病;溶解纖維蛋白的障礙;DNA / RNA研究;以及不同種族和人群在血栓性失血性疾病方面的差異。